Advertisement
Journal of Investigative Dermatology Home
Advanced SearchSave search

Masthead

Articles in Press

View All

This Month’s Highlights

Werth et al. report clinical improvement and tolerability following treatment with ALXN1830, a humanized antibody that blocks interactions between the neonatal Fc receptor and IgG, among 8 patients with chronic pemphigus, a blistering disease caused by pathogenic IgG autoantibodies to desmosome components. See the accompanying commentary. To learn more about the techniques used in this paper, visit this Research Techniques Made Simple article.

Yoon et al. demonstrate that the antimicrobial peptide LL-37, which has been implicated in rosacea, induces NLRP3 inflammasome activation in this inflammatory skin disorder and that genetic or pharmacological inhibition of the inflammasome abrogates this inflammation, supporting exploration of this therapeutic target in rosacea. See the accompanying commentary.

Wang et al describe a regulatory mechanism involving the XBP1‒MARCH5‒MFN2 axis, whereby mitochondrial fission and mitophagy are involved in the resistance to endoplasmic reticulum stress in melanoma cells. These findings may inform clinical advances as melanoma cells are often recalcitrant to endoplasmic reticulum stress, leading to tumor progression and therapeutic resistance. See the accompanying commentary. To learn more about the techniques used in this paper, visit this Research Techniques Made Simple article.

Research Techniques Made Simple
Recent Reviews
ESDR 2021 Meeting Abstract Supplement

About

Society for Investigative Dermatology (SID)

The Society for Investigative Dermatology (SID) advances science relevant to skin health and disease through education, advocacy, and scholarly exchange of scientific information.

European Society for Dermatological Research (ESDR)

The European Society for Dermatological Research (ESDR) supports research toward understanding skin homeostasis improving the health of patients suffering from skin and venereal disease, infectious diseases and immune-mediated and inflammatory disorders.

Metrics

Metrics

##
Impact Factor
##
5-Year Impact Factor
28 days
Average to First Decision

Most Read (Last 30 Days)

Most Cited (Previous 3 Years)

Advertisement
We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


RELX